Forkhead box O3 (FOXO3)

Where the papers sit

12 papers from the last 6 months study Forkhead box O3 (FOXO3) directly · updated from PubMed 3 Oct 2026

• Tissue Homeostasis and Disease

  Metabolic and stress signaling is being linked to immune tolerance, neuropathy, neuroinflammation, muscle loss and skeletal aging. AMPK, autophagy, lipid metabolism, TGF-β signaling and cellular senescence recur as routes connecting FOXO3 to disease phenotypes. Proposed interventions include retinoic acid, phillyrin-mediated 15-PGDH inhibition and pathway-focused metabolic modulation, but no single therapeutic strategy dominates. The shared direction is mechanistic mapping of FOXO3-associated tissue maintenance rather than a settled treatment approach.

  5 papers · 41.7%

• FOXO3 Autophagy in Disease

  Autophagy and mitochondrial quality control are being explored as ways to alter cancer growth, wound healing and tissue injury. Berberine targets mitophagy-related programs in breast cancer, while quercetin hydrogel activates FOXO3-mediated macrophage autophagy and M2 polarization in diabetic ulcers. AMPK/FOXO3 signaling is also used to suppress ferroptosis after myocardial ischemia-reperfusion, and macrophage senescence links the pathway to adverse pregnancy outcomes. The direction favors context-specific FOXO3 modulation, but the disease settings and interventions remain heterogeneous.

  4 papers · 33.3%

• FOXO3 in Oxidative Stress

  Antioxidant protection is the recurring aim, with FOXO3a positioned downstream of SIRT1 or AMPK to limit oxidative injury. SIRT1 reduces UVA photoaging by lowering FOXO3a acetylation, while gold nanoparticle–MOF materials target oxidative inflammation in atopic dermatitis. In epilepsy, AMPK–FOXO3a links glycolysis to ferroptosis suppression. The tissues differ, but the work converges on restoring FOXO3-dependent redox defenses.

  3 papers · 25%